OPRX OptimizeRx Corporation
USHealthcareAs of 2026-07-10 16:00
Why OPRX matters now
OptimizeRx Corporation (OPRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.41 with +2.07% on the session and $120.3M in market capitalization; recent performance reads 1-month +3.11% and YTD -59.38%.
The latest financial table shown here is Q1 2026, with revenue of $19.8M, net income of $-495.0K, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E 24.31 and FCF yield 15.3%.
The latest indexable market news headline is "OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.50; recent insider activity includes WASSON GREGORY D filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.31
PEG
0.19
P/B
0.72
P/S
0.87
EV/EBITDA
5.13
DCF Value
$-13.43
FCF Yield
15.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.0%
Operating Margin
13.6%
Net Margin
6.4%
ROE
5.5%
ROA
4.1%
ROIC
6.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.8M | $-495.0K | $-0.03 |
| Q4 2025 | $32.2M | $5.0M | $0.26 |
| FY 2025 | $109.4M | $5.1M | $0.27 |
| Q3 2025 | $26.1M | $779.0K | $0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.50
Target (Median)
$10.50
Target Range
$7.00 - $14.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
1.10
OptimizeRx Corporation is a digital health technology firm delivering a broad spectrum of solutions to life sciences organizations, healthcare providers, and patients. Its core offerings encompass financial messaging and a virtual patient support hub, enabling healthcare providers to seamlessly access sample vouchers, co-pay assistance, and other patient support resources directly within their electronic medical records (EMR) or e-prescribing platforms. The company also facilitates brand awareness and therapeutic communication through various messaging services, including targeted ads and unbranded educational content. Additionally, OptimizeRx consults with pharmaceutical manufacturers, guiding them in devising and executing effective eRx media strategies, which involves drug file integration, sales force education, and comprehensive strategy development for product promotion. It operates a cloud-based Mobile Health Messenger platform, offering interactive health messaging to bolster medication adherence and improve care coordination. Furthermore, a HIPAA-compliant automated mobile messaging platform empowers pharmaceutical companies and associated entities to directly connect with patients, fostering better regimen compliance. Patient-centric programs provide essential treatment and affordability details, alongside lifestyle and condition trackers, internet device integration, and tools for forms and surveys. For healthcare professionals, the company offers an evidence-based physician engagement solution that leverages real-world data. This tool helps identify patients suitable for particular therapies, raises awareness of patient access routes, and detects early signs of non-adherence within patient groups. Another key offering is a therapy initiation workflow designed to expedite patient access to treatments, especially those requiring extensive medical documentation from healthcare providers before pharmacists can dispense prescribed medications. Established in 2006, OptimizeRx is headquartered in Rochester, Michigan.